Literature DB >> 8623890

The treatment of Graves' ophthalmopathy in an incidence cohort.

G B Bartley1, V Fatourechi, E F Kadrmas, S J Jacobsen, D M Ilstrup, J A Garrity, C A Gorman.   

Abstract

PURPOSE: To determine the frequencies of medical and surgical treatments in an incidence cohort of 120 patients with Graves' ophthalmopathy.
METHODS: We reviewed the community medical records and administered a follow-up questionnaire.
RESULTS: Of the 120 patients, 89 (74.2%) required either no therapy or only supportive measures. Six patients (5.0%) were treated with systemic corticosteroids. One patient had orbital radiotherapy. Twenty-four patients (20.0%) underwent one or more surgical procedures. The cumulative probabilities of undergoing ophthalmic surgery of any type were 5.0% by one year after the diagnosis of ophthalmopathy, 9.3% after two years, 15.9% after five years, and 21.8% after ten years. The need for surgery was significantly related to age (P < .01; Cox proportional hazards model) but was not significantly dependent on gender (P = .5) or the interaction of age and gender (P = .15). The overall risk of the need for surgery was 2.6 times greater in patients older than 50 years (95% confidence interval, 1.2 to 5.8) than in younger patients. There were no significant differences between tobacco smokers and nonsmokers in the cumulative probabilities of undergoing surgery.
CONCLUSION: In 24 (20%) patients, one or more surgical procedures were used to treat Graves' ophthalmopathy. The probability of surgical intervention was significantly related to patient age (older than 50 years), but it was not related to gender or smoking.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623890     DOI: 10.1016/s0002-9394(14)70585-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  11 in total

1.  Factors Predicting the Success of Combined Orbital Decompression and Strabismus Surgery in Thyroid-Associated Orbitopathy.

Authors:  Meng-Wei Hsieh; Chih-Kang Hsu; Pao-Cheng Kuo; Hsu-Chieh Chang; Yi-Hao Chen; Ke-Hung Chien
Journal:  J Pers Med       Date:  2022-01-31

2.  Graves opthalmopathy and psychoendocrinopathies.

Authors:  Asaad A Ghanem; Mostafa A Amr; Lamiaa F Araafa
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

3.  Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes.

Authors:  Chris Y Wu; Leslie M Niziol; David C Musch; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

4.  No changes in serum concentrations of interleukin 10 (IL-10) and interferon gamma (IF-gamma) before and after treatment of the thyroid eye disease (TED).

Authors:  Nevenka Laban-Guceva; Magdalena Antova; Milco Bogoev
Journal:  Bosn J Basic Med Sci       Date:  2007-11       Impact factor: 3.363

Review 5.  [Endocrine orbitopathy 1998].

Authors:  G Förster; G Kahaly
Journal:  Med Klin (Munich)       Date:  1998-06-15

6.  Planning health care for patients with Graves' orbitopathy.

Authors:  Inna V Sasim; Tos T J M Berendschot; Chantal van Isterdael; Maarten P Mourits
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-26       Impact factor: 3.117

7.  Contrast sensitivity of thyroid associated ophthalmopathy patients without obvious optic neuropathy.

Authors:  Ümit Beden; Sümeyra Kaya; Volkan Yeter; Dilek Erkan
Journal:  ScientificWorldJournal       Date:  2013-12-24

Review 8.  Orbital decompression in thyroid eye disease.

Authors:  N Fichter; R F Guthoff; M P Schittkowski
Journal:  ISRN Ophthalmol       Date:  2012-11-12

Review 9.  Fat-removal orbital decompression for thyroid associated orbitopathy: The right procedure for the right patient.

Authors:  Eman Al-Sharif; Adel H Alsuhaibani
Journal:  Saudi J Ophthalmol       Date:  2017-06-14

Review 10.  Management of Thyroid Eye Disease-Related Strabismus.

Authors:  Mohammad Reza Akbari; Arash Mirmohammadsadeghi; Raziyeh Mahmoudzadeh; Amirreza Veisi
Journal:  J Curr Ophthalmol       Date:  2020-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.